OMNI Begins Clinical Evaluation of Active Spacer Tissue Balancing

OMNIlife science is evaluating the OMNIBotics® Active Spacer robotic tissue balancing device at three U.S. clinical sites. The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. Combined with the alignment and cutting guidance of OMNIBotics, the spacer is intended to help...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us